Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ketotifen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 1.00 |
| ▸ | DRD3 | P35462 | 7/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 4/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | HTR3A | P46098 | 3/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 3/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ketotifen SCHEMBL223510 | 1.00 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL4436 | 1.00 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL1170804 | 0.99 | DRD3 (0.97) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL3386047 | 0.99 | DRD3 (0.97) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL1171289 | 0.99 | DRD3 (0.97) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL28259803 | 0.97 | DRD3 (0.95) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL1171294 | 0.95 | DRD3 (0.91) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL9060252 | 0.94 | DRD3 (0.89) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL5968240 | 0.93 | DRD3 (0.87) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL1170677 | 0.91 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116298308-A | Metabolite markers associated with TSC-RAML differential diagnosis and prognosis prediction, and related products and uses | 中国医学科学院北京协和医院 | 2023-06-23 | — | — | CN | claimed |
| EP-4185286-A1 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | National University of Singapore (SG) | 2023-05-31 | — | — | EP | claimed |
| WO-2022019828-A1 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-01-27 | — | — | WO | claimed |
| US-20260144747-A1 | SYRUP PREPARATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-05-28 | — | — | US | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| EP-4566651-A2 | OPHTHALMIC DELIVERY DEVICE | Oxular Limited (GB) | 2025-06-11 | — | — | EP | disclosed |
| EP-4559922-A1 | ANTIHISTAMINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | HC Synthetic Pharmaceutical Co., Ltd. (CN) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024182745-A9 | COMPOSITIONS FOR TARGETING EXTRACELLULAR VESICLE TRAFFICKING AND METHODS THEREOF | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2025-01-16 | — | — | WO | disclosed |
| EP-4424313-A1 | SYRUP PREPARATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-09-04 | — | — | EP | disclosed |
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| CN-117794537-A | Solid dosage forms and dosing regimens comprising (2 r,3s,4s,5 r) -4- [ [3- (3, 4-difluoro-2-methoxy-phenyl) -4, 5-dimethyl-5- (trifluoromethyl) tetrahydrofuran-2-carbonyl ] amino ] pyridine-2-carboxamide | 沃泰克斯药物股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-114929340-A | Methods and agents for glaucoma | 奥夫博医疗创新有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022124243-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | 東和薬品株式会社 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022091925-A1 | ROPINIROLE-CONTAINING PATCH AND METHOD FOR IMPROVING SKIN PERMEABILITY OF ROPINIROLE | 久光製薬株式会社 | 2022-05-05 | — | — | WO | disclosed |
| WO-2022092284-A1 | COMPOSITION CONTAINING LIPID PEPTIDE AND SUCROSE ESTER | 日産化学株式会社 | 2022-05-05 | — | — | WO | disclosed |
| WO-2022070289-A1 | NITROGEN-CONTAINING BICYCLIC COMPOUND WHICH CONTAINS PYRIMIDINE | 旭化成ファーマ株式会社 | 2022-04-07 | — | — | WO | disclosed |
| WO-2022070287-A1 | MACROCYCLE COMPOUND | 旭化成ファーマ株式会社 | 2022-04-07 | — | — | WO | disclosed |
| WO-2022070288-A1 | NITROGEN-CONTAINING BICYCLIC COMPOUND | 旭化成ファーマ株式会社 | 2022-04-07 | — | — | WO | disclosed |
| WO-2022019828-A1 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-01-27 | — | — | WO | disclosed |
| EP-3943501-A1 | SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASES | Halozyme, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | JAK2, JAK1, JAK3 | HRH1 794/4885DRD3 4184/4885CHRM2 4780/4885 |
| US-20260144747-A1 | SYRUP PREPARATION | ALK, IRAK1, IRAK3 | HRH1 2423/4885DRD3 2214/4885CHRM2 1694/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | HRH1 3405/4885DRD3 4400/4885CHRM2 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.